Elanco Animal Health Incorporated (ELAN)
Elanco Animal Health Incorporated (ELAN) is a healthcare company (drug manufacturers - specialty & generic) based in the United States. The share price is $25.98, down 1.65% on the day, which values the company at $12.98B. Price as of 17 Nov 2026, 17:42 UTC, from Yahoo Finance.
Key facts
- Share price
- $25.98−1.65% today
- Market value
- $12.98B
- Forward P/E
- 20.1×
- Funk Score
- 28/100
- Against its own history
- Above its usual priceusual price $22.63
- 200-week average
- $16.1061% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Elanco Animal Health Incorporated in more detail
ELAN trades at 20.1× next year's expected earnings, 2.5× sales. Measured against its own history, the price is 15% above what its usual multiples would imply ($22.63) — above its usual price. It sits 61% above its 200-week average of $16.10.
Over the last five fiscal years Elanco Animal Health Incorporated has compounded revenue 7.6% a year. Its Funk Score is 28 out of 100 (financial strength 2.0, profitability 1.9, growth 5.0, value 2.2, each out of 10).
Worth checking: Altman Z in the distress zone; Thin interest cover.
5 of the superinvestors tracked here hold ELAN, including Dodge & Cox team (0.7% of the portfolio), Primecap team (0.6% of the portfolio), Charles Brandes (founder) (0.5% of the portfolio).
Superinvestors holding ELAN
5 of the investors tracked here report a position in their latest 13F filing.
- Dodge & Cox team Dodge & Cox0.74% of portfolio · $1.4B · trimmed · Q3 2026
- Primecap team Primecap Management0.63% of portfolio · $1B · trimmed · Q3 2026
- Charles Brandes (founder) Brandes Investment Partners0.50% of portfolio · $72.2M · added · Q3 2026
- Ken Griffin Citadel Advisors0.14% of portfolio · $237.9M · added · Q2 2026
- Lee Ainslie Maverick Capital0.02% of portfolio · $2.4M · trimmed · Q2 2026
Health Care companies of similar size
- BridgeBio PharmaBBIO
- Summit TherapeuticsSMMT
- GlaukosGKOS
- Encompass HealthEHC
- BrightSpring Health ServicesBTSG
- Baxter InternationalBAX
- Smith & NephewSNN
- PenumbraPEN
- Dr. Reddy's LaboratoriesRDY
- Align TechnologyALGN
- Cooper CompaniesCOO
- Fresenius Medical CareFMS
Side by side:ELAN vs BAX (Elanco Animal Health Incorporated vs Baxter International)ELAN vs BTSG (Elanco Animal Health Incorporated vs BrightSpring Health Services)ELAN vs EHC (Elanco Animal Health Incorporated vs Encompass Health)ELAN vs SNN (Elanco Animal Health Incorporated vs Smith & Nephew)ELAN vs GKOS (Elanco Animal Health Incorporated vs Glaukos)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Elanco Animal Health Incorporated (ELAN): questions and answers
What is ELAN's PEG ratio?
Elanco Animal Health Incorporated's PEG ratio is 4.04 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Elanco Animal Health Incorporated's market cap?
Elanco Animal Health Incorporated is valued at $12.98B at a share price of $25.98.
Is ELAN overvalued or undervalued?
Against its own history, ELAN is above its usual price: the price is 15% above the $22.63 implied by the median multiples it has traded at (price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is ELAN above its 200-week moving average?
Yes. ELAN is 61.3% above its 200-week average of $16.10. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Elanco Animal Health Incorporated growing?
Over the last five fiscal years Elanco Animal Health Incorporated's revenue grew 7.6% a year.
Does ELAN pay a dividend?
Elanco Animal Health Incorporated does not currently pay a regular dividend.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Elanco Animal Health Incorporated (ELAN) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ELAN
Underlying data: Yahoo Finance; company filings with the SEC.